Remitly Global Inc vs Revvity Inc — how do they compare? Remitly Global Inc trades at $23.37 (market cap $5.02B), while Revvity Inc trades at $110.67 (market cap $12.33B). The key difference: Revvity Inc is far larger — about 2.5× Remitly Global Inc's market cap, and Revvity Inc pays a 0.25% dividend while Remitly Global Inc pays none. Which is the better fit depends on your goals.
| RELY | RVTY | |
|---|---|---|
Market Cap | $5.02B | $12.33B |
Sector | Technology | Technology |
52-Week High | $25.23 | $117.75 |
52-Week Low | $12.20 | $82.26 |
Enterprise Value | $4.41B | $14.82B |
Dividend Yield | — | 0.25% |
Signals from Pluang's Aura AI — not financial advice
RELY trades at $23.83, down 1.24% on the day, with a bullish technical signal from moving averages. The company has demonstrated a strong turnaround, achieving profitability in 2025 with net income of $67.93 million after years of losses. Revenue growth is robust, reaching $1.64 billion in 2025, with positive cash flow from operations of $325.08 million. Recent news highlights expansion, including a new license in the UAE and raised full-year guidance for 2026.
The outlook is positive, driven by accelerating revenue growth, market share gains in the remittance sector, and a clear path to sustained profitability. Key risks include intense competition from established payment giants and execution challenges in international expansion. With a consensus analyst price target of $28.50 implying significant upside, the stock presents a growth opportunity, though investors should be mindful of its premium valuation multiples.
RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.
The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.
Trailing returns across standard periods
Latest headlines on both assets
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →